BiotechTube

Allogeneic NK Cells

Phase 2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Refractory Rheumatoid Arthritis (RA)

Conditions

Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease

Trial Timeline

Jul 9, 2025 → Jan 1, 2029

NCT ID
NCT06991114

About Allogeneic NK Cells

Allogeneic NK Cells is a phase 2 stage product being developed by Artiva Biotherapeutics for Refractory Rheumatoid Arthritis (RA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06991114. Target conditions include Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc).

What happened to similar drugs?

3 of 20 similar drugs in Refractory Rheumatoid Arthritis (RA) were approved

Approved (3) Terminated (1) Active (16)
🔄CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
🔄perampanel + perampanel + perampanel + PlaceboEisaiPhase 3
🔄E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3
🔄E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3
❌RufinamideEisaiPhase 3
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06991114Phase 2Recruiting

Competing Products

20 competing products in Refractory Rheumatoid Arthritis (RA)

See all competitors
ProductCompanyStageHype Score
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-2736ModernaPhase 1
0
mRNA-2808ModernaPhase 2
0
mRNA-2416ModernaPhase 2
0
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
agenT-797MiNK TherapeuticsPhase 1
19
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
Valemetostat TosylateDaiichi SankyoPhase 2
39
EnzalutamideAstellas PharmaPhase 2
35
ASP1650Astellas PharmaPhase 2
35
YM598Astellas PharmaPhase 2
27
erlotinib + etoposideAstellas PharmaPhase 2
27
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
39
Lenvatinib + EverolimusEisaiPhase 1/2
32
perampanel + perampanel + perampanel + PlaceboEisaiPhase 3
40
Eribulin mesilate + Irinotecan hydrochlorideEisaiPhase 1/2
32
perampanelEisaiPhase 2
35
rabeprazole sodiumEisaiPre-clinical
26
LenvatinibEisaiPhase 2
35